Influenza A virus vaccine H5N1 - Fluart Innovative Vaccines

Drug Profile

Influenza A virus vaccine H5N1 - Fluart Innovative Vaccines

Alternative Names: Fluval H5N1; Fluval P H5N1; Monovalent influenza A H5N1 vaccine - Fluart Innovative Vaccines

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omninvest
  • Developer Fluart Innovative Vaccines
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 08 Sep 2008 Launched for Influenza-A virus H5N1 subtype (prevention) in Hungary (IM)
  • 27 Sep 2007 National Institute of Pharmacy issues final marketing authorisation for Influenza A virus vaccine H5N1 in Hungary (first global approval)
  • 14 Mar 2006 Registered for in Influenza A virus infections H5N1 in Hungary (IM) (temporary approval granted)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top